Protagenic Therapeutics Inc new  (PTIX)
Other Ticker:  
Price: $0.9036 $-0.10 -9.640%
Day's High: $0.9284 Week Perf: -4.88 %
Day's Low: $ 0.86 30 Day Perf: -49.78 %
Volume (M): 18 52 Wk High: $ 2.22
Volume (M$): $ 16 52 Wk Avg: $1.29
Open: $0.91 52 Wk Low: $0.68

 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 4
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Protagenic Therapeutics Inc New
Protagenic Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative drugs for the treatment of neuropsychiatric disorders. The company is known for its groundbreaking research in targeting the sigma-1 receptor (S1R), an emerging therapeutic target with potential benefits for a range of conditions, including depression, anxiety, and neurodegenerative diseases.

Protagenic Therapeutics utilizes a unique approach called Quantitative Systems Pharmacology (QSP) to identify and develop drugs that modulate the activity of S1R. By comprehensively understanding the intricate molecular pathways involved in neuropsychiatric disorders, the company aims to design precise and effective treatments that can alleviate symptoms and improve patient outcomes.

The company's research efforts have yielded promising results, with several drug candidates in development. Protagenic Therapeutics' lead candidate, PT00114, has shown potential as an antidepressant and cognitive enhancer in preclinical studies. Other candidates in their pipeline target different aspects of neuropsychiatric disorders, such as neuroinflammation and neurodegeneration.

Protagenic Therapeutics is committed to advancing its drug candidates into clinical trials in order to validate their efficacy and safety profiles. The company also collaborates with academic institutions and pharmaceutical partners to accelerate the development process and bring new treatments to patients more efficiently.

Overall, Protagenic Therapeutics Inc is at the forefront of developing novel therapies for neuropsychiatric disorders, utilizing innovative approaches and targeting the sigma-1 receptor to address unmet medical needs in this field.

   Company Address: 149 Fifth Avenue New York 10010 NY
   Company Phone Number: 994-8200   Stock Exchange / Ticker: NASDAQ PTIX


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Protagenic Therapeutics Inc New

Pharmaceutical Preparations Company Faces Significant Operating Deficit in Latest Financial Report

Protagenic Therapeutics Inc (PTIX) has recently announced its earnings for the January to March 31, 2024 period, and although shareholders had not anticipated any significant changes at the top-line, the company's operating deficit has raised some concerns. During this time, the operating deficit amounted to $-1.738359 million, indicating a significant worsening compared to the first quarter of 2023 when it stood at $-0.739294 million.
However, what has caught the attention of analysts is the speculation surrounding whether Protagenic Therapeutics Inc will soon begin reporting revenue. It comes as no surprise that the company reported a net loss of $-1.724 million, which has increased from the net loss of $-0.718 million in the first quarter of 2023.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com